<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.1d3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76004</article-id><article-id pub-id-type="doi">10.7554/eLife.76004</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Evolutionary Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Physics of Living Systems</subject></subj-group></article-categories><title-group><article-title>Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-264355"><name><surname>LaMont</surname><given-names>Colin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-182456"><name><surname>Otwinowski</surname><given-names>Jakub</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264351"><name><surname>Vanshylla</surname><given-names>Kanika</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-264352"><name><surname>Gruell</surname><given-names>Henning</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0725-7138</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-100896"><name><surname>Klein</surname><given-names>Florian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-162124"><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6245-3553</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><institution>Max Planck Institute for Dynamics and Self-Organization</institution>, <addr-line><named-content content-type="city">Göttingen</named-content></addr-line>, <country>Germany</country></aff><aff id="aff2"><institution>University of Cologne</institution>, <addr-line><named-content content-type="city">Cologne</named-content></addr-line>, <country>Germany</country></aff><aff id="aff3"><institution content-type="dept">Department of Physics</institution>, <institution>University of Washington</institution>, <addr-line><named-content content-type="city">Seattle</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-240886"><name><surname>Sprenger</surname><given-names>Kayla</given-names></name><role>Reviewing editor</role><aff><institution>MIT</institution>, </aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>armita@uw.edu</email> (AN);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>07</month><year>2022</year></pub-date><volume>11</volume><elocation-id>e76004</elocation-id><history><date date-type="received"><day>01</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>04</day><month>07</month><year>2022</year></date></history><permissions><copyright-statement>© 2022, LaMont et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>LaMont et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-76004-v1.pdf"/><abstract><p>Infusion of broadly neutralizing antibodies (bNAbs) has shown promise as an alternative to anti-retroviral therapy against HIV. A key challenge is to suppress viral escape, which is more effectively achieved with a combination of bNAbs. Here, we propose a computational approach to predict the efficacy of a bNAb therapy based on the population genetics of HIV escape, which we parametrize using high-throughput HIV sequence data from bNAb-naive patients. By quantifying the mutational target size and the fitness cost of HIV-1 escape from bNAbs, we predict the distribution of rebound times in three clinical trials. We show that a cocktail of three bNAbs is necessary to effectively suppress viral escape, and predict the optimal composition of such bNAb cocktail. Our results offer a rational therapy design for HIV, and show how genetic data can be used to predict treatment outcomes and design new approaches to pathogenic control.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001659</institution-id><institution>Deutsche Forschungsgemeinschaft</institution></institution-wrap></funding-source><award-id>1310</award-id><principal-award-recipient><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>2045054</award-id><principal-award-recipient><name><surname>Nourmohammad</surname><given-names>Armita</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution>1Max Planck Institute for Dynamics and Self-organization</institution></institution-wrap></funding-source><award-id>open access funding</award-id><principal-award-recipient><name><surname>LaMont</surname><given-names>Colin</given-names></name><name><surname>Otwinowski</surname><given-names>Jakub</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Armita Nourmohammad, Reviewing editor, <italic>eLife</italic>.</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>The current manuscript is a computational study, so no data have been generated for this manuscript. Reference to the previously published data used in this manuscript is provided.  Modelling code is uploaded on GitHub at https://github.com/StatPhysBio/HIVTreatmentOptimization, and in the Julia package https://github.com/StatPhysBio/EscapeSimulator.</p><p>The following previously published datasets were used:</p><p><element-citation id="dataset1" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Zanini et al</collab></person-group><year iso-8601-date="2015">2015</year><source>Project: PRJEB9618</source><ext-link ext-link-type="uri" xlink:href="https://www.ebi.ac.uk/ena/browser/view/PRJEB9618?show=reads">https://www.ebi.ac.uk/ena/browser/view/PRJEB9618?show=reads</ext-link><comment>European Nucleotide Archive, Accession no: PRJEB9618</comment></element-citation><element-citation id="dataset2" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Caskey et al</collab></person-group><year iso-8601-date="2015">2015</year><source>HIV-1 isolate 2A1_DB7_02 from USA envelope glycoprotein (env) gene, partial cds</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/1036347437">https://www.ncbi.nlm.nih.gov/nuccore/1036347437</ext-link><comment>GeneBank, accession no: KX016803</comment></element-citation><element-citation id="dataset3" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Caskey et al</collab></person-group><year iso-8601-date="2017">2017</year><source>Antibody 10-1074 suppresses viremia in HIV-1-infected individuals</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/KY323724">https://www.ncbi.nlm.nih.gov/nuccore/KY323724</ext-link><comment>GeneBank, accession no: KY323724-KY324834</comment></element-citation><element-citation id="dataset4" publication-type="data" specific-use="references"><person-group person-group-type="author"><collab>Bar-On et al</collab></person-group><year iso-8601-date="2018">2018</year><source>Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals</source><ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/nuccore/MH632763">https://www.ncbi.nlm.nih.gov/nuccore/MH632763</ext-link><comment>GeneBank, accession no: MH632763 - MH633255</comment></element-citation></p></sec><supplementary-material><ext-link xlink:href="elife-76004-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>